CZ296810B6 - Léciva pro lécbu nádoru - Google Patents

Info

Publication number

CZ296810B6

CZ296810B6 CZ0165798A CZ165798A CZ296810B6 CZ 296810 B6 CZ296810 B6 CZ 296810B6 CZ 0165798 A CZ0165798 A CZ 0165798A CZ 165798 A CZ165798 A CZ 165798A CZ 296810 B6 CZ296810 B6 CZ 296810B6

Authority

CZ

Czechia

Prior art keywords

tumor

cells

expression

gene

cell

Prior art date

1995-11-30

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims description 149
• 239000003814 drug Substances 0.000 title claims description 13
• 230000014509 gene expression Effects 0.000 claims abstract description 116
• 238000011282 treatment Methods 0.000 claims abstract description 52
• 210000004881 tumor cell Anatomy 0.000 claims abstract description 49
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 35
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 35
• 239000002157 polynucleotide Substances 0.000 claims abstract description 35
• 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract description 17
• 239000013603 viral vector Substances 0.000 claims abstract description 9
• 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 7
• 108090000623 proteins and genes Proteins 0.000 claims description 151
• 241000701161 unidentified adenovirus Species 0.000 claims description 86
• 239000013598 vector Substances 0.000 claims description 72
• 241000282414 Homo sapiens Species 0.000 claims description 50
• 239000013604 expression vector Substances 0.000 claims description 47
• 208000015181 infectious disease Diseases 0.000 claims description 45
• 238000002347 injection Methods 0.000 claims description 31
• 239000007924 injection Substances 0.000 claims description 31
• 230000010076 replication Effects 0.000 claims description 27
• 201000011510 cancer Diseases 0.000 claims description 24
• 230000002950 deficient Effects 0.000 claims description 24
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
• 201000010099 disease Diseases 0.000 claims description 21
• 239000012623 DNA damaging agent Substances 0.000 claims description 20
• 230000003612 virological effect Effects 0.000 claims description 19
• 230000001225 therapeutic effect Effects 0.000 claims description 18
• 239000002245 particle Substances 0.000 claims description 16
• 230000001177 retroviral effect Effects 0.000 claims description 15
• 238000012360 testing method Methods 0.000 claims description 15
• 239000003795 chemical substances by application Substances 0.000 claims description 14
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 14
• 201000001441 melanoma Diseases 0.000 claims description 13
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
• 210000004185 liver Anatomy 0.000 claims description 12
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
• 201000010536 head and neck cancer Diseases 0.000 claims description 11
• 230000002458 infectious effect Effects 0.000 claims description 11
• 208000020816 lung neoplasm Diseases 0.000 claims description 10
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
• 238000002271 resection Methods 0.000 claims description 10
• 201000009030 Carcinoma Diseases 0.000 claims description 9
• 102000004127 Cytokines Human genes 0.000 claims description 9
• 108090000695 Cytokines Proteins 0.000 claims description 9
• 210000003128 head Anatomy 0.000 claims description 9
• 230000010412 perfusion Effects 0.000 claims description 8
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
• 210000001072 colon Anatomy 0.000 claims description 7
• 229960002949 fluorouracil Drugs 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• -1 pl6 Proteins 0.000 claims description 7
• 229920001184 polypeptide Polymers 0.000 claims description 7
• 108010002350 Interleukin-2 Proteins 0.000 claims description 6
• 102000000588 Interleukin-2 Human genes 0.000 claims description 6
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
• 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 6
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 6
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 6
• 230000003211 malignant effect Effects 0.000 claims description 6
• 210000000214 mouth Anatomy 0.000 claims description 6
• 229960005420 etoposide Drugs 0.000 claims description 5
• 210000003800 pharynx Anatomy 0.000 claims description 5
• 210000003491 skin Anatomy 0.000 claims description 5
• 108090000467 Interferon-beta Proteins 0.000 claims description 4
• 108010002616 Interleukin-5 Proteins 0.000 claims description 4
• 108090001005 Interleukin-6 Proteins 0.000 claims description 4
• 102000004889 Interleukin-6 Human genes 0.000 claims description 4
• 229940009456 adriamycin Drugs 0.000 claims description 4
• 239000002246 antineoplastic agent Substances 0.000 claims description 4
• 210000004556 brain Anatomy 0.000 claims description 4
• 210000000867 larynx Anatomy 0.000 claims description 4
• 210000003437 trachea Anatomy 0.000 claims description 4
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 3
• 108010092160 Dactinomycin Proteins 0.000 claims description 3
• 206010018338 Glioma Diseases 0.000 claims description 3
• 206010039491 Sarcoma Diseases 0.000 claims description 3
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
• 229940127093 camptothecin Drugs 0.000 claims description 3
• 229940127089 cytotoxic agent Drugs 0.000 claims description 3
• 229960000640 dactinomycin Drugs 0.000 claims description 3
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 3
• 210000003238 esophagus Anatomy 0.000 claims description 3
• 229960004857 mitomycin Drugs 0.000 claims description 3
• 210000003281 pleural cavity Anatomy 0.000 claims description 3
• 230000003439 radiotherapeutic effect Effects 0.000 claims description 3
• 210000003932 urinary bladder Anatomy 0.000 claims description 3
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
• 108700020463 BRCA1 Proteins 0.000 claims description 2
• 102000036365 BRCA1 Human genes 0.000 claims description 2
• 101150072950 BRCA1 gene Proteins 0.000 claims description 2
• 208000032612 Glial tumor Diseases 0.000 claims description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
• 102100026720 Interferon beta Human genes 0.000 claims description 2
• 102000003814 Interleukin-10 Human genes 0.000 claims description 2
• 108090000174 Interleukin-10 Proteins 0.000 claims description 2
• 102000013462 Interleukin-12 Human genes 0.000 claims description 2
• 108010065805 Interleukin-12 Proteins 0.000 claims description 2
• 102000003816 Interleukin-13 Human genes 0.000 claims description 2
• 108090000176 Interleukin-13 Proteins 0.000 claims description 2
• 108010002386 Interleukin-3 Proteins 0.000 claims description 2
• 108090000978 Interleukin-4 Proteins 0.000 claims description 2
• 108010002586 Interleukin-7 Proteins 0.000 claims description 2
• 108010002335 Interleukin-9 Proteins 0.000 claims description 2
• 102000000585 Interleukin-9 Human genes 0.000 claims description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
• 210000000988 bone and bone Anatomy 0.000 claims description 2
• 210000000481 breast Anatomy 0.000 claims description 2
• 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
• 229960004679 doxorubicin Drugs 0.000 claims description 2
• YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims description 2
• 210000003739 neck Anatomy 0.000 claims description 2
• 210000001672 ovary Anatomy 0.000 claims description 2
• 210000000496 pancreas Anatomy 0.000 claims description 2
• 229910052697 platinum Inorganic materials 0.000 claims description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 2
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims description 2
• 229960001237 podophyllotoxin Drugs 0.000 claims description 2
• YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims description 2
• 210000002307 prostate Anatomy 0.000 claims description 2
• 210000002784 stomach Anatomy 0.000 claims description 2
• 210000001550 testis Anatomy 0.000 claims description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
• 229960001722 verapamil Drugs 0.000 claims description 2
• 101150040622 Dp gene Proteins 0.000 claims 1
• 102100037850 Interferon gamma Human genes 0.000 claims 1
• 108010047761 Interferon-alpha Proteins 0.000 claims 1
• 102000006992 Interferon-alpha Human genes 0.000 claims 1
• 108010074328 Interferon-gamma Proteins 0.000 claims 1
• 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 claims 1
• 210000000683 abdominal cavity Anatomy 0.000 claims 1
• 102000055104 bcl-X Human genes 0.000 claims 1
• 108700000711 bcl-X Proteins 0.000 claims 1
• 201000006385 lung benign neoplasm Diseases 0.000 claims 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 claims 1
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 70
• 238000001727 in vivo Methods 0.000 abstract description 41
• 210000004027 cell Anatomy 0.000 description 333
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 228
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 220
• 238000012546 transfer Methods 0.000 description 86
• 241000700605 Viruses Species 0.000 description 53
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 50
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 46
• 241001465754 Metazoa Species 0.000 description 45
• 102000004169 proteins and genes Human genes 0.000 description 41
• 210000001519 tissue Anatomy 0.000 description 40
• 238000003752 polymerase chain reaction Methods 0.000 description 39
• 108700025694 p53 Genes Proteins 0.000 description 38
• 230000000694 effects Effects 0.000 description 37
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
• 230000012010 growth Effects 0.000 description 34
• 239000000203 mixture Substances 0.000 description 34
• 235000018102 proteins Nutrition 0.000 description 34
• 241000700159 Rattus Species 0.000 description 31
• 238000004458 analytical method Methods 0.000 description 30
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 28
• 230000001404 mediated effect Effects 0.000 description 28
• 239000002953 phosphate buffered saline Substances 0.000 description 28
• 230000006907 apoptotic process Effects 0.000 description 25
• 238000001415 gene therapy Methods 0.000 description 24
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
• 108020004999 messenger RNA Proteins 0.000 description 23
• 238000010186 staining Methods 0.000 description 23
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
• 150000001413 amino acids Chemical class 0.000 description 22
• 238000000338 in vitro Methods 0.000 description 22
• 235000001014 amino acid Nutrition 0.000 description 20
• 239000002502 liposome Substances 0.000 description 20
• 229940024606 amino acid Drugs 0.000 description 18
• 238000006243 chemical reaction Methods 0.000 description 18
• 238000002474 experimental method Methods 0.000 description 18
• 239000002609 medium Substances 0.000 description 18
• 102000039446 nucleic acids Human genes 0.000 description 18
• 108020004707 nucleic acids Proteins 0.000 description 18
• 150000007523 nucleic acids Chemical class 0.000 description 18
• 108020004635 Complementary DNA Proteins 0.000 description 17
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
• 230000001965 increasing effect Effects 0.000 description 17
• 238000002560 therapeutic procedure Methods 0.000 description 17
• 241000766026 Coregonus nasus Species 0.000 description 16
• 238000003556 assay Methods 0.000 description 16
• 238000010804 cDNA synthesis Methods 0.000 description 16
• 239000002299 complementary DNA Substances 0.000 description 16
• 239000000523 sample Substances 0.000 description 16
• 210000002966 serum Anatomy 0.000 description 16
• 241000699670 Mus sp. Species 0.000 description 15
• 238000002512 chemotherapy Methods 0.000 description 15
• 238000002360 preparation method Methods 0.000 description 15
• 108020003175 receptors Proteins 0.000 description 15
• 102000005962 receptors Human genes 0.000 description 15
• 210000002700 urine Anatomy 0.000 description 15
• 239000000872 buffer Substances 0.000 description 14
• 238000009472 formulation Methods 0.000 description 14
• 239000012528 membrane Substances 0.000 description 14
• 239000000243 solution Substances 0.000 description 14
• 241000195493 Cryptophyta Species 0.000 description 13
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
• 108700020796 Oncogene Proteins 0.000 description 13
• 230000010261 cell growth Effects 0.000 description 13
• 210000004379 membrane Anatomy 0.000 description 13
• 230000005855 radiation Effects 0.000 description 13
• 230000004044 response Effects 0.000 description 13
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
• 230000000295 complement effect Effects 0.000 description 12
• 230000000120 cytopathologic effect Effects 0.000 description 12
• 210000002950 fibroblast Anatomy 0.000 description 12
• 239000013612 plasmid Substances 0.000 description 12
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 11
• 230000001640 apoptogenic effect Effects 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 230000035772 mutation Effects 0.000 description 11
• 230000004614 tumor growth Effects 0.000 description 11
• 241001135569 Human adenovirus 5 Species 0.000 description 10
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
• 230000005540 biological transmission Effects 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 239000012153 distilled water Substances 0.000 description 10
• 239000003623 enhancer Substances 0.000 description 10
• 238000002991 immunohistochemical analysis Methods 0.000 description 10
• 230000000306 recurrent effect Effects 0.000 description 10
• 238000001356 surgical procedure Methods 0.000 description 10
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
• 101150080074 TP53 gene Proteins 0.000 description 9
• 239000012634 fragment Substances 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 201000005202 lung cancer Diseases 0.000 description 9
• 210000004962 mammalian cell Anatomy 0.000 description 9
• 239000003550 marker Substances 0.000 description 9
• 241001430294 unidentified retrovirus Species 0.000 description 9
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
• 230000005778 DNA damage Effects 0.000 description 8
• 231100000277 DNA damage Toxicity 0.000 description 8
• 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 8
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
• 108020005202 Viral DNA Proteins 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 150000001875 compounds Chemical class 0.000 description 8
• 239000012091 fetal bovine serum Substances 0.000 description 8
• 239000013642 negative control Substances 0.000 description 8
• 239000002773 nucleotide Substances 0.000 description 8
• 125000003729 nucleotide group Chemical group 0.000 description 8
• 230000002018 overexpression Effects 0.000 description 8
• 238000007920 subcutaneous administration Methods 0.000 description 8
• 238000013518 transcription Methods 0.000 description 8
• 230000035897 transcription Effects 0.000 description 8
• 238000001890 transfection Methods 0.000 description 8
• 238000001262 western blot Methods 0.000 description 8
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 7
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 7
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 7
• 102100034349 Integrase Human genes 0.000 description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
• 208000011589 adenoviridae infectious disease Diseases 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 238000001574 biopsy Methods 0.000 description 7
• 239000013553 cell monolayer Substances 0.000 description 7
• 230000004663 cell proliferation Effects 0.000 description 7
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
• 229960004316 cisplatin Drugs 0.000 description 7
• 231100000673 dose–response relationship Toxicity 0.000 description 7
• 230000002068 genetic effect Effects 0.000 description 7
• 210000003494 hepatocyte Anatomy 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 238000002372 labelling Methods 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 208000010370 Adenoviridae Infections Diseases 0.000 description 6
• 206010060931 Adenovirus infection Diseases 0.000 description 6
• 241000701022 Cytomegalovirus Species 0.000 description 6
• 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 6
• 108091034117 Oligonucleotide Proteins 0.000 description 6
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
• 230000000692 anti-sense effect Effects 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 230000004927 fusion Effects 0.000 description 6
• 238000012744 immunostaining Methods 0.000 description 6
• 238000002513 implantation Methods 0.000 description 6
• 230000002601 intratumoral effect Effects 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 238000004806 packaging method and process Methods 0.000 description 6
• 230000008488 polyadenylation Effects 0.000 description 6
• 239000013641 positive control Substances 0.000 description 6
• 238000001959 radiotherapy Methods 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 230000001629 suppression Effects 0.000 description 6
• 230000009885 systemic effect Effects 0.000 description 6
• 230000008685 targeting Effects 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• 239000004475 Arginine Substances 0.000 description 5
• 239000004471 Glycine Substances 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
• 239000004472 Lysine Substances 0.000 description 5
• 239000007983 Tris buffer Substances 0.000 description 5
• 239000013504 Triton X-100 Substances 0.000 description 5
• 229920004890 Triton X-100 Polymers 0.000 description 5
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 238000003782 apoptosis assay Methods 0.000 description 5
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
• 108010005774 beta-Galactosidase Proteins 0.000 description 5
• 238000013467 fragmentation Methods 0.000 description 5
• 238000006062 fragmentation reaction Methods 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
• 230000002055 immunohistochemical effect Effects 0.000 description 5
• 230000006882 induction of apoptosis Effects 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 230000005764 inhibitory process Effects 0.000 description 5
• 230000000977 initiatory effect Effects 0.000 description 5
• 230000003902 lesion Effects 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000035945 sensitivity Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 230000001988 toxicity Effects 0.000 description 5
• 231100000419 toxicity Toxicity 0.000 description 5
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
• 230000005748 tumor development Effects 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 210000001835 viscera Anatomy 0.000 description 5
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
• 108700028369 Alleles Proteins 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 108091026890 Coding region Proteins 0.000 description 4
• 108020004705 Codon Proteins 0.000 description 4
• 206010009944 Colon cancer Diseases 0.000 description 4
• 108020004414 DNA Proteins 0.000 description 4
• 101710113436 GTPase KRas Proteins 0.000 description 4
• 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
• 206010053759 Growth retardation Diseases 0.000 description 4
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• 206010028851 Necrosis Diseases 0.000 description 4
• 102000043276 Oncogene Human genes 0.000 description 4
• 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 4
• 241000283973 Oryctolagus cuniculus Species 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 239000002202 Polyethylene glycol Substances 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 108010067390 Viral Proteins Proteins 0.000 description 4
• 239000011543 agarose gel Substances 0.000 description 4
• 235000004279 alanine Nutrition 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000030833 cell death Effects 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 210000000349 chromosome Anatomy 0.000 description 4
• 239000002131 composite material Substances 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
• 210000000981 epithelium Anatomy 0.000 description 4
• 238000000605 extraction Methods 0.000 description 4
• 238000000684 flow cytometry Methods 0.000 description 4
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
• 230000001939 inductive effect Effects 0.000 description 4
• 230000010354 integration Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 108010054155 lysyllysine Proteins 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 230000004660 morphological change Effects 0.000 description 4
• 230000017074 necrotic cell death Effects 0.000 description 4
• 239000012188 paraffin wax Substances 0.000 description 4
• 102000013415 peroxidase activity proteins Human genes 0.000 description 4
• 108040007629 peroxidase activity proteins Proteins 0.000 description 4
• 239000001103 potassium chloride Substances 0.000 description 4
• 235000011164 potassium chloride Nutrition 0.000 description 4
• 238000001556 precipitation Methods 0.000 description 4
• 230000005522 programmed cell death Effects 0.000 description 4
• 108010014186 ras Proteins Proteins 0.000 description 4
• 102000016914 ras Proteins Human genes 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 238000010361 transduction Methods 0.000 description 4
• 230000026683 transduction Effects 0.000 description 4
• 241001515965 unidentified phage Species 0.000 description 4
• WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 3
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
• 206010001258 Adenoviral infections Diseases 0.000 description 3
• 241000512259 Ascophyllum nodosum Species 0.000 description 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• 208000005623 Carcinogenesis Diseases 0.000 description 3
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
• 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 3
• 102000053602 DNA Human genes 0.000 description 3
• 230000004543 DNA replication Effects 0.000 description 3
• AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
• 206010061818 Disease progression Diseases 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 241000700721 Hepatitis B virus Species 0.000 description 3
• CTGZVVQVIBSOBB-AVGNSLFASA-N His-His-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O CTGZVVQVIBSOBB-AVGNSLFASA-N 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• 241000598171 Human adenovirus sp. Species 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• 101710128836 Large T antigen Proteins 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• 102000043131 MHC class II family Human genes 0.000 description 3
• 108091054438 MHC class II family Proteins 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 102000048850 Neoplasm Genes Human genes 0.000 description 3
• 108700019961 Neoplasm Genes Proteins 0.000 description 3
• 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 3
• 238000010222 PCR analysis Methods 0.000 description 3
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 208000007660 Residual Neoplasm Diseases 0.000 description 3
• 238000002105 Southern blotting Methods 0.000 description 3
• 108010006785 Taq Polymerase Proteins 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 102000006601 Thymidine Kinase Human genes 0.000 description 3
• 108020004440 Thymidine kinase Proteins 0.000 description 3
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 108010070944 alanylhistidine Proteins 0.000 description 3
• 230000000259 anti-tumor effect Effects 0.000 description 3
• 230000005875 antibody response Effects 0.000 description 3
• 108010068380 arginylarginine Proteins 0.000 description 3
• 108010084541 asialoorosomucoid Proteins 0.000 description 3
• 235000009582 asparagine Nutrition 0.000 description 3
• 229960001230 asparagine Drugs 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 230000036952 cancer formation Effects 0.000 description 3
• 231100000504 carcinogenesis Toxicity 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 238000002701 cell growth assay Methods 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 238000002591 computed tomography Methods 0.000 description 3
• 238000012864 cross contamination Methods 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 230000005750 disease progression Effects 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 230000009036 growth inhibition Effects 0.000 description 3
• 239000001963 growth medium Substances 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000000984 immunochemical effect Effects 0.000 description 3
• 238000011532 immunohistochemical staining Methods 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 230000002779 inactivation Effects 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 230000003907 kidney function Effects 0.000 description 3
• 239000006193 liquid solution Substances 0.000 description 3
• 229910001629 magnesium chloride Inorganic materials 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 231100001221 nontumorigenic Toxicity 0.000 description 3
• 238000011580 nude mouse model Methods 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000013610 patient sample Substances 0.000 description 3
• 210000003200 peritoneal cavity Anatomy 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• 108010012581 phenylalanylglutamate Proteins 0.000 description 3
• 150000003904 phospholipids Chemical class 0.000 description 3
• 230000001766 physiological effect Effects 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000022983 regulation of cell cycle Effects 0.000 description 3
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
• 238000010839 reverse transcription Methods 0.000 description 3
• 238000003757 reverse transcription PCR Methods 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000000527 sonication Methods 0.000 description 3
• 230000010473 stable expression Effects 0.000 description 3
• 230000004083 survival effect Effects 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 238000002626 targeted therapy Methods 0.000 description 3
• 238000011285 therapeutic regimen Methods 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000001131 transforming effect Effects 0.000 description 3
• 238000002604 ultrasonography Methods 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• 230000029812 viral genome replication Effects 0.000 description 3
• 210000002845 virion Anatomy 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
• 206010002091 Anaesthesia Diseases 0.000 description 2
• 108020005544 Antisense RNA Proteins 0.000 description 2
• NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 2
• JVMKBJNSRZWDBO-FXQIFTODSA-N Arg-Cys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O JVMKBJNSRZWDBO-FXQIFTODSA-N 0.000 description 2
• CRCCTGPNZUCAHE-DCAQKATOSA-N Arg-His-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CN=CN1 CRCCTGPNZUCAHE-DCAQKATOSA-N 0.000 description 2
• CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 2
• 102100026189 Beta-galactosidase Human genes 0.000 description 2
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• 108090000565 Capsid Proteins Proteins 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 102100023321 Ceruloplasmin Human genes 0.000 description 2
• 108060005980 Collagenase Proteins 0.000 description 2
• 102000029816 Collagenase Human genes 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• HAYVTMHUNMMXCV-IMJSIDKUSA-N Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CS HAYVTMHUNMMXCV-IMJSIDKUSA-N 0.000 description 2
• CPTUXCUWQIBZIF-ZLUOBGJFSA-N Cys-Asn-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CPTUXCUWQIBZIF-ZLUOBGJFSA-N 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
• 241000702421 Dependoparvovirus Species 0.000 description 2
• 102000001301 EGF receptor Human genes 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 108010067770 Endopeptidase K Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 206010015150 Erythema Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 206010064571 Gene mutation Diseases 0.000 description 2
• ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 2
• BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 description 2
• UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 2
• UUTGYDAKPISJAO-JYJNAYRXSA-N Glu-Tyr-Leu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 UUTGYDAKPISJAO-JYJNAYRXSA-N 0.000 description 2
• PMSDOVISAARGAV-FHWLQOOXSA-N Glu-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 PMSDOVISAARGAV-FHWLQOOXSA-N 0.000 description 2
• CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 2
• 229920002527 Glycogen Polymers 0.000 description 2
• 102100037907 High mobility group protein B1 Human genes 0.000 description 2
• 101710168537 High mobility group protein B1 Proteins 0.000 description 2
• BXOLYFJYQQRQDJ-MXAVVETBSA-N His-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)N BXOLYFJYQQRQDJ-MXAVVETBSA-N 0.000 description 2
• WSEITRHJRVDTRX-QTKMDUPCSA-N His-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CN=CN1)N)O WSEITRHJRVDTRX-QTKMDUPCSA-N 0.000 description 2
• 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 2
• VNDQNDYEPSXHLU-JUKXBJQTSA-N Ile-His-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N VNDQNDYEPSXHLU-JUKXBJQTSA-N 0.000 description 2
• AXNGDPAKKCEKGY-QPHKQPEJSA-N Ile-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N AXNGDPAKKCEKGY-QPHKQPEJSA-N 0.000 description 2
• PHRWFSFCNJPWRO-PPCPHDFISA-N Ile-Leu-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N PHRWFSFCNJPWRO-PPCPHDFISA-N 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• 108010050904 Interferons Proteins 0.000 description 2
• 102000014150 Interferons Human genes 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• KWTVLKBOQATPHJ-SRVKXCTJSA-N Leu-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)N KWTVLKBOQATPHJ-SRVKXCTJSA-N 0.000 description 2
• YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• HKCCVDWHHTVVPN-CIUDSAMLSA-N Lys-Asp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O HKCCVDWHHTVVPN-CIUDSAMLSA-N 0.000 description 2
• NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 2
• 238000011887 Necropsy Methods 0.000 description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
• MPGJIHFJCXTVEX-KKUMJFAQSA-N Phe-Arg-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O MPGJIHFJCXTVEX-KKUMJFAQSA-N 0.000 description 2
• 241000276498 Pollachius virens Species 0.000 description 2
• 108010071690 Prealbumin Proteins 0.000 description 2
• 102000007584 Prealbumin Human genes 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 230000006819 RNA synthesis Effects 0.000 description 2
• UCOYFSCEIWQYNL-FXQIFTODSA-N Ser-Cys-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(O)=O UCOYFSCEIWQYNL-FXQIFTODSA-N 0.000 description 2
• BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 2
• CRJZZXMAADSBBQ-SRVKXCTJSA-N Ser-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO CRJZZXMAADSBBQ-SRVKXCTJSA-N 0.000 description 2
• SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 2
• 102000054727 Serum Amyloid A Human genes 0.000 description 2
• 108700028909 Serum Amyloid A Proteins 0.000 description 2
• 241000700584 Simplexvirus Species 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• 239000012163 TRI reagent Substances 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
• 206010045169 Tumour flare Diseases 0.000 description 2
• PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 108020002494 acetyltransferase Proteins 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 230000037005 anaesthesia Effects 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 108010062796 arginyllysine Proteins 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 108010047857 aspartylglycine Proteins 0.000 description 2
• 238000011717 athymic nude mouse Methods 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
• 230000027455 binding Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 239000013599 cloning vector Substances 0.000 description 2
• 229960002424 collagenase Drugs 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 239000003184 complementary RNA Substances 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 239000005549 deoxyribonucleoside Substances 0.000 description 2
• FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000012154 double-distilled water Substances 0.000 description 2
• 238000001493 electron microscopy Methods 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 231100000321 erythema Toxicity 0.000 description 2
• 229960005542 ethidium bromide Drugs 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 108700004026 gag Genes Proteins 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 108010017007 glucose-regulated proteins Proteins 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 229940096919 glycogen Drugs 0.000 description 2
• 101150028578 grp78 gene Proteins 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 238000010562 histological examination Methods 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 239000002054 inoculum Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 108010034529 leucyl-lysine Proteins 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 108010005942 methionylglycine Proteins 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 230000017095 negative regulation of cell growth Effects 0.000 description 2
• 230000009826 neoplastic cell growth Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 210000004882 non-tumor cell Anatomy 0.000 description 2
• 238000012758 nuclear staining Methods 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 108091008819 oncoproteins Proteins 0.000 description 2
• 210000004789 organ system Anatomy 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 239000000276 potassium ferrocyanide Substances 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002203 pretreatment Methods 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 239000002510 pyrogen Substances 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000003362 replicative effect Effects 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 210000001082 somatic cell Anatomy 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 2
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
• 229950003937 tolonium Drugs 0.000 description 2
• HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000010474 transient expression Effects 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• 239000001226 triphosphate Substances 0.000 description 2
• 235000011178 triphosphate Nutrition 0.000 description 2
• UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
• 239000002753 trypsin inhibitor Substances 0.000 description 2
• 230000004565 tumor cell growth Effects 0.000 description 2
• 230000005740 tumor formation Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 230000005760 tumorsuppression Effects 0.000 description 2
• 230000002100 tumorsuppressive effect Effects 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 238000012800 visualization Methods 0.000 description 2
• 239000008096 xylene Substances 0.000 description 2
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
• 235000007173 Abies balsamea Nutrition 0.000 description 1
• 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
• 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
• NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
• HHRAXZAYZFFRAM-CIUDSAMLSA-N Ala-Leu-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O HHRAXZAYZFFRAM-CIUDSAMLSA-N 0.000 description 1
• XUCHENWTTBFODJ-FXQIFTODSA-N Ala-Met-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O XUCHENWTTBFODJ-FXQIFTODSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 244000144725 Amygdalus communis Species 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 108020003566 Antisense Oligodeoxyribonucleotides Proteins 0.000 description 1
• VYSRNGOMGHOJCK-GUBZILKMSA-N Arg-Ala-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N VYSRNGOMGHOJCK-GUBZILKMSA-N 0.000 description 1
• OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 description 1
• KJGNDQCYBNBXDA-GUBZILKMSA-N Arg-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N KJGNDQCYBNBXDA-GUBZILKMSA-N 0.000 description 1
• IIABBYGHLYWVOS-FXQIFTODSA-N Arg-Asn-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O IIABBYGHLYWVOS-FXQIFTODSA-N 0.000 description 1
• RKQRHMKFNBYOTN-IHRRRGAJSA-N Arg-His-Lys Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N RKQRHMKFNBYOTN-IHRRRGAJSA-N 0.000 description 1
• DPLFNLDACGGBAK-KKUMJFAQSA-N Arg-Phe-Glu Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N DPLFNLDACGGBAK-KKUMJFAQSA-N 0.000 description 1
• NLRJGXZWTKXRHP-DCAQKATOSA-N Asn-Leu-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NLRJGXZWTKXRHP-DCAQKATOSA-N 0.000 description 1
• ORJQQZIXTOYGGH-SRVKXCTJSA-N Asn-Lys-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ORJQQZIXTOYGGH-SRVKXCTJSA-N 0.000 description 1
• OROMFUQQTSWUTI-IHRRRGAJSA-N Asn-Phe-Arg Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N OROMFUQQTSWUTI-IHRRRGAJSA-N 0.000 description 1
• VLDRQOHCMKCXLY-SRVKXCTJSA-N Asn-Ser-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O VLDRQOHCMKCXLY-SRVKXCTJSA-N 0.000 description 1
• PIABYSIYPGLLDQ-XVSYOHENSA-N Asn-Thr-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PIABYSIYPGLLDQ-XVSYOHENSA-N 0.000 description 1
• AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 1
• YSYTWUMRHSFODC-QWRGUYRKSA-N Asn-Tyr-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O YSYTWUMRHSFODC-QWRGUYRKSA-N 0.000 description 1
• NJPLPRFQLBZAMH-IHRRRGAJSA-N Asn-Tyr-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(O)=O NJPLPRFQLBZAMH-IHRRRGAJSA-N 0.000 description 1
• JGDBHIVECJGXJA-FXQIFTODSA-N Asp-Asp-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JGDBHIVECJGXJA-FXQIFTODSA-N 0.000 description 1
• QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 1
• DWBZEJHQQIURML-IMJSIDKUSA-N Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O DWBZEJHQQIURML-IMJSIDKUSA-N 0.000 description 1
• ZBYLEBZCVKLPCY-FXQIFTODSA-N Asp-Ser-Arg Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ZBYLEBZCVKLPCY-FXQIFTODSA-N 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 241000711404 Avian avulavirus 1 Species 0.000 description 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
• 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 108010077805 Bacterial Proteins Proteins 0.000 description 1
• 239000004857 Balsam Substances 0.000 description 1
• 208000004860 Blast Crisis Diseases 0.000 description 1
• 101100228200 Caenorhabditis elegans gly-5 gene Proteins 0.000 description 1
• 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 235000014036 Castanea Nutrition 0.000 description 1
• 241001070941 Castanea Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 206010057248 Cell death Diseases 0.000 description 1
• 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 1
• 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
• 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 239000012624 DNA alkylating agent Substances 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 238000007399 DNA isolation Methods 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 231100001074 DNA strand break Toxicity 0.000 description 1
• 241000450599 DNA viruses Species 0.000 description 1
• 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 101710096438 DNA-binding protein Proteins 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 108090000204 Dipeptidase 1 Proteins 0.000 description 1
• 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 1
• 241000725618 Duck hepatitis B virus Species 0.000 description 1
• 101150005585 E3 gene Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
• 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
• 102100039328 Endoplasmin Human genes 0.000 description 1
• 101710091045 Envelope protein Proteins 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 108010020195 FLAG peptide Proteins 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 102000054184 GADD45 Human genes 0.000 description 1
• 102100030708 GTPase KRas Human genes 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
• JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
• LTUVYLVIZHJCOQ-KKUMJFAQSA-N Glu-Arg-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LTUVYLVIZHJCOQ-KKUMJFAQSA-N 0.000 description 1
• QPRZKNOOOBWXSU-CIUDSAMLSA-N Glu-Asp-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N QPRZKNOOOBWXSU-CIUDSAMLSA-N 0.000 description 1
• YBAFDPFAUTYYRW-YUMQZZPRSA-N Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O YBAFDPFAUTYYRW-YUMQZZPRSA-N 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 description 1
• PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
• ICUTTWWCDIIIEE-BQBZGAKWSA-N Gly-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN ICUTTWWCDIIIEE-BQBZGAKWSA-N 0.000 description 1
• FXLVSYVJDPCIHH-STQMWFEESA-N Gly-Phe-Arg Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FXLVSYVJDPCIHH-STQMWFEESA-N 0.000 description 1
• WDXLKVQATNEAJQ-BQBZGAKWSA-N Gly-Pro-Asp Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WDXLKVQATNEAJQ-BQBZGAKWSA-N 0.000 description 1
• IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
• YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 1
• OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 1
• FGPLUIQCSKGLTI-WDSKDSINSA-N Gly-Ser-Glu Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O FGPLUIQCSKGLTI-WDSKDSINSA-N 0.000 description 1
• LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 1
• FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 1
• FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
• YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
• 102100035660 Glyceraldehyde-3-phosphate dehydrogenase, testis-specific Human genes 0.000 description 1
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
• JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
• 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 1
• 101150112743 HSPA5 gene Proteins 0.000 description 1
• 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
• 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 206010019695 Hepatic neoplasm Diseases 0.000 description 1
• 101710155188 Hexon-interlacing protein Proteins 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
• 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
• 101100281953 Homo sapiens GAPDH gene Proteins 0.000 description 1
• 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
• 101100462513 Homo sapiens TP53 gene Proteins 0.000 description 1
• 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 241000701096 Human adenovirus 7 Species 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• QLRMMMQNCWBNPQ-QXEWZRGKSA-N Ile-Arg-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N QLRMMMQNCWBNPQ-QXEWZRGKSA-N 0.000 description 1
• ZUWSVOYKBCHLRR-MGHWNKPDSA-N Ile-Tyr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUWSVOYKBCHLRR-MGHWNKPDSA-N 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 244000018716 Impatiens biflora Species 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• HGCNKOLVKRAVHD-UHFFFAOYSA-N L-Met-L-Phe Natural products CSCCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 HGCNKOLVKRAVHD-UHFFFAOYSA-N 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• 108010001831 LDL receptors Proteins 0.000 description 1
• 206010023856 Laryngeal squamous cell carcinoma Diseases 0.000 description 1
• 101710192606 Latent membrane protein 2 Proteins 0.000 description 1
• 241000880493 Leptailurus serval Species 0.000 description 1
• ULXYQAJWJGLCNR-YUMQZZPRSA-N Leu-Asp-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O ULXYQAJWJGLCNR-YUMQZZPRSA-N 0.000 description 1
• HIZYETOZLYFUFF-BQBZGAKWSA-N Leu-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O HIZYETOZLYFUFF-BQBZGAKWSA-N 0.000 description 1
• HFBCHNRFRYLZNV-GUBZILKMSA-N Leu-Glu-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HFBCHNRFRYLZNV-GUBZILKMSA-N 0.000 description 1
• OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 1
• BQVUABVGYYSDCJ-ZFWWWQNUSA-N Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-ZFWWWQNUSA-N 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 206010024769 Local reaction Diseases 0.000 description 1
• WXJKFRMKJORORD-DCAQKATOSA-N Lys-Arg-Ala Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](N)CCCCN WXJKFRMKJORORD-DCAQKATOSA-N 0.000 description 1
• UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 1
• MXMDJEJWERYPMO-XUXIUFHCSA-N Lys-Ile-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MXMDJEJWERYPMO-XUXIUFHCSA-N 0.000 description 1
• ORVFEGYUJITPGI-IHRRRGAJSA-N Lys-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCCN ORVFEGYUJITPGI-IHRRRGAJSA-N 0.000 description 1
• WBSCNDJQPKSPII-KKUMJFAQSA-N Lys-Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O WBSCNDJQPKSPII-KKUMJFAQSA-N 0.000 description 1
• PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
• YFQSSOAGMZGXFT-MEYUZBJRSA-N Lys-Thr-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YFQSSOAGMZGXFT-MEYUZBJRSA-N 0.000 description 1
• IMDJSVBFQKDDEQ-MGHWNKPDSA-N Lys-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)N IMDJSVBFQKDDEQ-MGHWNKPDSA-N 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108010031099 Mannose Receptor Proteins 0.000 description 1
• 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
• SBSIKVMCCJUCBZ-GUBZILKMSA-N Met-Asn-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N SBSIKVMCCJUCBZ-GUBZILKMSA-N 0.000 description 1
• CEGVMWAVGBRVFS-XGEHTFHBSA-N Met-Cys-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CEGVMWAVGBRVFS-XGEHTFHBSA-N 0.000 description 1
• GFDBWMDLBKCLQH-IHRRRGAJSA-N Met-Phe-Cys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N GFDBWMDLBKCLQH-IHRRRGAJSA-N 0.000 description 1
• 206010027463 Metastases to pleura Diseases 0.000 description 1
• 206010027468 Metastases to spine Diseases 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 1
• 101100078999 Mus musculus Mx1 gene Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
• 108091061960 Naked DNA Proteins 0.000 description 1
• BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
• 241001028048 Nicola Species 0.000 description 1
• 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 1
• 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 1
• 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 208000035539 Ovarian infection Diseases 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 241001631646 Papillomaviridae Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• RFCVXVPWSPOMFJ-STQMWFEESA-N Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 RFCVXVPWSPOMFJ-STQMWFEESA-N 0.000 description 1
• XZQYIJALMGEUJD-OEAJRASXSA-N Phe-Lys-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XZQYIJALMGEUJD-OEAJRASXSA-N 0.000 description 1
• 108010089430 Phosphoproteins Proteins 0.000 description 1
• 102000007982 Phosphoproteins Human genes 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 241000243142 Porifera Species 0.000 description 1
• 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 102100038358 Prostate-specific antigen Human genes 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 101710150114 Protein rep Proteins 0.000 description 1
• 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 1
• 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 1
• 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
• 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
• 239000012083 RIPA buffer Substances 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 101000868151 Rattus norvegicus Somatotropin Proteins 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 101710152114 Replication protein Proteins 0.000 description 1
• 108010034634 Repressor Proteins Proteins 0.000 description 1
• 102000009661 Repressor Proteins Human genes 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
• 241000714474 Rous sarcoma virus Species 0.000 description 1
• 230000018199 S phase Effects 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 108091006627 SLC12A9 Proteins 0.000 description 1
• 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
• 241000277331 Salmonidae Species 0.000 description 1
• 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
• JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
• SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
• NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
• OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 1
• LDEBVRIURYMKQS-WISUUJSJSA-N Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO LDEBVRIURYMKQS-WISUUJSJSA-N 0.000 description 1
• 241001522306 Serinus serinus Species 0.000 description 1
• 108010032838 Sialoglycoproteins Proteins 0.000 description 1
• 102000007365 Sialoglycoproteins Human genes 0.000 description 1
• 206010067868 Skin mass Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 208000036844 Squamous cell carcinoma of the larynx Diseases 0.000 description 1
• 206010041857 Squamous cell carcinoma of the oral cavity Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 108010008038 Synthetic Vaccines Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 108700026226 TATA Box Proteins 0.000 description 1
• 238000012288 TUNEL assay Methods 0.000 description 1
• 239000004809 Teflon Substances 0.000 description 1
• 229920006362 Teflon® Polymers 0.000 description 1
• 101710109576 Terminal protein Proteins 0.000 description 1
• CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 description 1
• UZJDBCHMIQXLOQ-HEIBUPTGSA-N Thr-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O UZJDBCHMIQXLOQ-HEIBUPTGSA-N 0.000 description 1
• UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 1
• IQHUITKNHOKGFC-MIMYLULJSA-N Thr-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IQHUITKNHOKGFC-MIMYLULJSA-N 0.000 description 1
• FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 1
• WCRFXRIWBFRZBR-GGVZMXCHSA-N Thr-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WCRFXRIWBFRZBR-GGVZMXCHSA-N 0.000 description 1
• 102000011923 Thyrotropin Human genes 0.000 description 1
• 108010061174 Thyrotropin Proteins 0.000 description 1
• 102100023132 Transcription factor Jun Human genes 0.000 description 1
• 101710195626 Transcriptional activator protein Proteins 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 101000862137 Trichoderma koningii Glyceraldehyde-3-phosphate dehydrogenase 1 Proteins 0.000 description 1
• 101001025013 Trichoderma koningii Glyceraldehyde-3-phosphate dehydrogenase 2 Proteins 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
• KLQPIEVIKOQRAW-IZPVPAKOSA-N Tyr-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KLQPIEVIKOQRAW-IZPVPAKOSA-N 0.000 description 1
• 102000003425 Tyrosinase Human genes 0.000 description 1
• 108060008724 Tyrosinase Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
• 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 102100031083 Uteroglobin Human genes 0.000 description 1
• 108090000203 Uteroglobin Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 102100035071 Vimentin Human genes 0.000 description 1
• 108010065472 Vimentin Proteins 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 241000269370 Xenopus <genus> Species 0.000 description 1
• VRGWBRLULZUWAJ-XFFXIZSCSA-N [(2s)-2-[(1r,3z,5s,8z,12z,15s)-5,17-dihydroxy-4,8,12,15-tetramethyl-16-oxo-18-bicyclo[13.3.0]octadeca-3,8,12,17-tetraenyl]propyl] acetate Chemical compound C1\C=C(C)/CC\C=C(C)/CC[C@H](O)\C(C)=C/C[C@@H]2C([C@@H](COC(C)=O)C)=C(O)C(=O)[C@]21C VRGWBRLULZUWAJ-XFFXIZSCSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 230000001133 acceleration Effects 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
• 229960005054 acepromazine Drugs 0.000 description 1
• 102000005421 acetyltransferase Human genes 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 229940021704 adenovirus vaccine Drugs 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 210000005058 airway cell Anatomy 0.000 description 1
• 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 235000020224 almond Nutrition 0.000 description 1
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
• 108010090535 alpha-albumin Proteins 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000003263 anti-adenoviral effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000003293 antisense oligodeoxyribonucleotide Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 230000009118 appropriate response Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 101150036080 at gene Proteins 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 238000011888 autopsy Methods 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 102000006635 beta-lactamase Human genes 0.000 description 1
• 239000003012 bilayer membrane Substances 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000007844 bleaching agent Substances 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 208000023913 breast extraskeletal osteosarcoma Diseases 0.000 description 1
• 201000002858 breast osteosarcoma Diseases 0.000 description 1
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
• 230000005907 cancer growth Effects 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 210000000234 capsid Anatomy 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 101150055766 cat gene Proteins 0.000 description 1
• 230000025084 cell cycle arrest Effects 0.000 description 1
• 230000012820 cell cycle checkpoint Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000005023 cervical esophagus Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000010428 chromatin condensation Effects 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 230000024321 chromosome segregation Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• 231100000026 common toxicity Toxicity 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 239000003433 contraceptive agent Substances 0.000 description 1
• 230000002254 contraceptive effect Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229940109239 creatinine Drugs 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 238000012303 cytoplasmic staining Methods 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 231100000517 death Toxicity 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 238000000326 densiometry Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 238000007598 dipping method Methods 0.000 description 1
• 230000009433 disease-worsening effect Effects 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 230000003503 early effect Effects 0.000 description 1
• 230000000459 effect on growth Effects 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 108700004025 env Genes Proteins 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000011536 extraction buffer Substances 0.000 description 1
• 235000013861 fat-free Nutrition 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 239000003517 fume Substances 0.000 description 1
• VRGWBRLULZUWAJ-UHFFFAOYSA-N fusaproliferin Natural products C1C=C(C)CCC=C(C)CCC(O)C(C)=CCC2C(C(COC(C)=O)C)=C(O)C(=O)C21C VRGWBRLULZUWAJ-UHFFFAOYSA-N 0.000 description 1
• 101150098622 gag gene Proteins 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000012637 gene transfection Methods 0.000 description 1
• 230000008303 genetic mechanism Effects 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 108010049041 glutamylalanine Proteins 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
• 108010081551 glycylphenylalanine Proteins 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 239000003630 growth substance Substances 0.000 description 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 230000003067 hemagglutinative effect Effects 0.000 description 1
• 230000002008 hemorrhagic effect Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 102000043283 human SERPINE1 Human genes 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 206010021198 ichthyosis Diseases 0.000 description 1
• 238000007654 immersion Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 108700027921 interferon tau Proteins 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 230000001678 irradiating effect Effects 0.000 description 1
• 108010027338 isoleucylcysteine Proteins 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 201000005264 laryngeal carcinoma Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 239000012160 loading buffer Substances 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 108010009298 lysylglutamic acid Proteins 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 238000007726 management method Methods 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
• YYGBVRCTHASBKD-UHFFFAOYSA-M methylene green Chemical compound [Cl-].C1=CC(N(C)C)=C([N+]([O-])=O)C2=[S+]C3=CC(N(C)C)=CC=C3N=C21 YYGBVRCTHASBKD-UHFFFAOYSA-M 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 239000002991 molded plastic Substances 0.000 description 1
• 238000000329 molecular dynamics simulation Methods 0.000 description 1
• 238000009126 molecular therapy Methods 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 230000000869 mutational effect Effects 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 210000001989 nasopharynx Anatomy 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 230000018901 negative regulation of programmed cell death Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 208000025440 neoplasm of neck Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 230000004942 nuclear accumulation Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 208000010655 oral cavity squamous cell carcinoma Diseases 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 238000007427 paired t-test Methods 0.000 description 1
• 210000003254 palate Anatomy 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 210000004923 pancreatic tissue Anatomy 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 238000009520 phase I clinical trial Methods 0.000 description 1
• 150000002989 phenols Chemical class 0.000 description 1
• 108010073101 phenylalanylleucine Proteins 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 108010025488 pinealon Proteins 0.000 description 1
• 108700004029 pol Genes Proteins 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000009597 pregnancy test Methods 0.000 description 1
• 230000001855 preneoplastic effect Effects 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 229930185346 proliferin Natural products 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
• 230000009396 radiation induced apoptosis Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
• 229940124551 recombinant vaccine Drugs 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000026267 regulation of growth Effects 0.000 description 1
• 230000037425 regulation of transcription Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 230000000979 retarding effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 210000005181 root of the tongue Anatomy 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229930182490 saponin Natural products 0.000 description 1
• 150000007949 saponins Chemical class 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• VVLFAAMTGMGYBS-UHFFFAOYSA-M sodium;4-[[4-(ethylamino)-3-methylphenyl]-(4-ethylimino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-3-sulfobenzenesulfonate Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S(O)(=O)=O)=C1C=C(C)C(=NCC)C=C1 VVLFAAMTGMGYBS-UHFFFAOYSA-M 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000007480 spreading Effects 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 238000003153 stable transfection Methods 0.000 description 1
• 239000012192 staining solution Substances 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 108091007196 stromelysin Proteins 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 231100000057 systemic toxicity Toxicity 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 238000010863 targeted diagnosis Methods 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 229940113082 thymine Drugs 0.000 description 1
• 230000026727 thymocyte apoptotic process Effects 0.000 description 1
• 239000005495 thyroid hormone Substances 0.000 description 1
• 229940036555 thyroid hormone Drugs 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 239000006163 transport media Substances 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 238000013042 tunel staining Methods 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 108010051110 tyrosyl-lysine Proteins 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 210000005048 vimentin Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1